Oncology
3 drugs are in development for Non-Hodgkin Lymphoma.
- Companies
- 3
- Clinical trials
- 37
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Non-Hodgkin Lymphoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(2)
Phase 1/Phase 2(1)
About this indication
Non-Hodgkin Lymphoma context
Oncology·MeSH: Lymphoma, Non-Hodgkin (D008228)
Also known as: Diffuse Small Cleaved Cell Lymphoma, Lymphoma, Atypical Diffuse Small Lymphoid, Lymphoma, Non Hodgkin's, Lymphoma, Nonhodgkin, Lymphoma, Small Cleaved Cell, Diffuse, Nonhodgkin's Lymphoma
Prevalence
50.0 / 100K
Incidence
17.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Non-Hodgkin Lymphoma?
BioSniper tracks 3 drugs in development for Non-Hodgkin Lymphoma across 3 companies.
How many clinical trials target Non-Hodgkin Lymphoma?
There are 37 clinical trials targeting Non-Hodgkin Lymphoma tracked by BioSniper.
What is the prevalence of Non-Hodgkin Lymphoma?
The estimated prevalence of Non-Hodgkin Lymphoma is approximately 50.0 per 100,000 population.